Selinexor Form A Crystallization for Stable, High-Purity Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for thermodynamically stable and suitable crystalline forms of Selinexor (KG8) for use in pharmaceutical compositions that exhibit good dissolution properties, flow characteristics, and high yield and purity, as well as methods for their efficient preparation.
Innovation Solution
The development of crystalline forms of Selinexor, specifically Forms A, B, C, and D, characterized by distinct X-ray powder diffraction peaks, which can be prepared through methods involving slurry formation, heating, cooling, and solvent systems, enabling high yield and purity, and conversion between forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If amorphous or unstable crystalline forms of Selinexor are used, then the compound can be obtained, but the pharmaceutical composition exhibits poor stability and dissolution properties
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing specific crystalline forms (Forms A, B, C, D) with distinct X-ray powder diffraction patterns, melting points, and thermodynamic properties. Form A was selected as the optimal crystalline form because it exhibits the best combination of stability, dissolution rate, and flow properties. This systematic characterization and selection of specific physical parameters resolves the contradiction by providing a stable, manufacturable crystalline form.
Solution Approach 2:
The patent utilizes phase transitions by describing methods to convert between different crystalline forms of Selinexor. Specifically, Form D can be converted to Form A through controlled heating and cooling cycles, and Form B can be converted to Form A through slurry treatment. These phase transition methods enable the manufacture of the stable Form A from other forms, resolving the contradiction between stability and ease of manufacture.
2Stability of the object's composition
If a crystalline form with high stability is selected, then pharmaceutical suitability is improved, but dissolution rate and bioavailability may be reduced
Solution Approach 1:
The patent resolves this contradiction by identifying Form A as the optimal crystalline form that achieves the right balance between stability and dissolution. Form A exhibits superior dissolution properties compared to other crystalline forms while maintaining high chemical stability. The specific crystal structure of Form A, characterized by its unique X-ray powder diffraction pattern and melting point, provides both stability and adequate dissolution rate for pharmaceutical use.
3Manufacturing precision
If multiple crystalline forms are characterized and converted between, then high purity and yield are achieved, but the process complexity increases
Solution Approach 1:
The patent applies phase transitions to achieve high purity through controlled conversions between crystalline forms. Form D serves as an intermediate that can be converted to pure Form A through controlled heating and cooling. This phase transition approach allows for purification while maintaining a manageable process complexity, as the conversions follow predictable thermal pathways.
Solution Approach 2:
The patent uses Form D as an intermediary crystalline form in the conversion process to Form A. This intermediary form facilitates high-purity manufacturing by serving as a stable intermediate that can be reliably converted to the final Form A product. The intermediary approach simplifies the overall process by breaking down the purification into manageable steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of Selinexor, particularly Form A, offer high stability, dissolution, and purity, facilitating their use in pharmaceutical compositions with improved manufacturing efficiency and oral bioavailability.
Implementation Method 1
Single crystalline Form A is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 4.4°, 19.9°, 21.3° and 22.0°
Implementation Method 2
Single crystalline Form A is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 4.4°, 19.9°, 21.3° and 22.0°
Implementation Method 3
The development of crystalline forms of Selinexor, specifically Forms A, B, C, and D, characterized by distinct X-ray powder diffraction peaks, which can be prepared through methods involving slurry formation, heating, cooling, and solvent systems
Data Source
AI summary
The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.